Page last updated: 2024-12-04

ornithine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth

Description

Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6262
CHEMBL ID446143
CHEBI ID15729
SCHEMBL ID8579
MeSH IDM0015430

Synonyms (83)

Synonym
AC-13803
gtpl725
CHEBI:15729 ,
(s)-alpha,delta-diaminovaleric acid
(s)-ornithine
(2s)-2,5-diaminopentanoic acid
ornithine, l-
ornithinum [latin]
ornitina [spanish]
einecs 200-731-7
ornithine [inn]
brn 1722298
l( )-ornithine
ornithine (van)
ORN ,
SMP2_000009
ornithine, l- (8ci)
l-ornithine (9ci)
pentanoic acid, 2,5-diamino-, (s)-
alpha, delta-diaminovaleric acid
(+)-s-ornithine
l-norvaline, 5-amino-
pentanoic acid, 2,5-diamino
l-(-)-ornithine
L-ORNITHINE ,
(s)-2,5-diaminopentanoic acid
C00077
70-26-8
(s)-2,5-diaminovaleric acid
(s)-2,5-diaminopentanoate
ornithine
1HQG
levo-ornithine
3JDW
1LAH
DB00129
8AB10027-4D34-488A-9F55-E86692CA2853
CHEMBL446143
nsc-758894
ornithine, (l)-isomer
BMSE000162
D08302
ornithine (inn)
AKOS006239312
nsc758894
pharmakon1600-01504524
25104-12-5
ornitina
4-04-00-02644 (beilstein handbook reference)
unii-e524n2ixa3
l(-)-ornithine
nsc 758894
e524n2ixa3 ,
ornithinum
ornithine [mi]
ornithine [inci]
ornithine [mart.]
lysine acetate impurity e [ep impurity]
ornithine [who-dd]
S4857
AHLPHDHHMVZTML-BYPYZUCNSA-N
SCHEMBL8579
CS-4817
NCGC00263569-01
W-104562
HY-B1352
l-ornithine2,5-diaminovalericacid
bdbm50487430
(s)-a,d-diaminovalerate
(s)-a,d-diaminovaleric acid
l-ornithine, hcl
Q410198
S4653
5-diaminopentanoic acid
(s)-2
mfcd00242584
EN300-96942
(r,s)-2,5-diamino-pentanoic acid
DTXSID00883219
A866639
l-ornithine;2,5-diaminovaleric acid
()-ornithine
AS-80993

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These results suggest that thrombocytopenia is the major dose-limiting side-effect of continuous DFMO infusion but does not occur at a dose of 500 mg/kg body wt/day."( Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion.
Ajani, JA; Grossie, VB; Nishioka, K; Ota, DM; Stephens, LC, 1986
)
0.27
" The intraperitoneal administration of toxic doses of l-2,4-diaminobutyric acid to rats resulted in hyperirritability, tremors and convulsions in 12-20hr."( The 'neurotoxicity' of L-2,4-diaminobutyric acid.
Chen, CH; Koeppe, RE; Meghal, SK; O'Neal, RM; Reynolds, CS, 1968
)
0.25
" Both drugs were judged too toxic to justify intrathecal or intraventricular studies with these agents in patients."( CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBG in beagle dogs.
Borcich, JK; Byrd, D; Campbell, J; Davis, RL; Levin, VA, 1984
)
0.27
" Spermine proved highly toxic and growth rates were reduced compared with controls when even ."( Toxicity and growth-promoting potential of spermine when fed to chicks.
Smith, TK; Sousadias, MG, 1995
)
0.29
"Two main trials and three preliminary experiments were conducted in order to examine adverse effects of excess lysine in 140- to 150-kg Holstein bull calves."( Adverse effects of excess lysine in calves.
Abe, M; Funaba, M; Iriki, T; Kaneshige, K; Kuwashima, K; Sato, H; Watanabe, S, 2001
)
0.31
" In addition to dose-response and glial protection, experiments were also conducted to determine whether toxic effects were due to apoptosis."( Beta-amyloid toxicity in embryonic rat astrocytes.
Assis-Nascimento, P; Jarvis, KM; Montague, JR; Mudd, LM, 2007
)
0.34
" In the absence of controlled trials, it is currently not possible to estimate a safe upper limit for either of these 2 amino acids."( Glutamine metabolism and function in relation to proline synthesis and the safety of glutamine and proline supplementation.
Watford, M, 2008
)
0.35
" Thirty serious adverse events were reported in 28 patients (15 allocated to OKG and 13 to placebo)."( Efficacy and safety of ornithine alpha-ketoglutarate in heel pressure ulcers in elderly patients: results of a randomized controlled trial.
Bourdel Marchasson, I; Constans, T; Kerihuel, JC; Kern, J; Lerebours, E; Meaume, S; Teot, L, 2009
)
0.35
" The present paper summarizes the occurrence of alkaloids in the food chain, their mode of action and possible adverse effects including a safety assessment."( Alkaloids in the human food chain--natural occurrence and possible adverse effects.
Dusemund, B; Koleva, II; Rietjens, IM; Soffers, AE; van Beek, TA, 2012
)
0.38
" OP is safe in healthy subjects and in stable patients with cirrhosis, but there are no data in decompensated cirrhosis."( Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Arranz, JA; Blanco, A; Córdoba, J; Fuentes, I; Riudor, E; Simón-Talero, M; Soriano, G; Suñé, P; Torrens, M; Ventura-Cots, M,
)
0.13
"No severe adverse events were observed."( Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Arranz, JA; Blanco, A; Córdoba, J; Fuentes, I; Riudor, E; Simón-Talero, M; Soriano, G; Suñé, P; Torrens, M; Ventura-Cots, M,
)
0.13
"OP is a safe and well-tolerated drug in decompensated cirrhotics that may decrease plasma ammonia by inducing its appearance as phenylacetylglutamine in urine."( Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Arranz, JA; Blanco, A; Córdoba, J; Fuentes, I; Riudor, E; Simón-Talero, M; Soriano, G; Suñé, P; Torrens, M; Ventura-Cots, M,
)
0.13
" These results indicate that dietary supplementation with L-arginine (up to 630 mg/kg body weight/day) is safe in pigs for at least 91 days."( Safety of long-term dietary supplementation with L-arginine in pigs.
Hu, S; Li, X; McNeal, CJ; Meininger, CJ; Rezaei, R; Wu, G, 2015
)
0.42
" These rankings correlate with in vivo data and demonstrate successful application of the assay to rank a series of related toxic and non-toxic compounds."( A human induced pluripotent stem cell-based in vitro assay predicts developmental toxicity through a retinoic acid receptor-mediated pathway for a series of related retinoid analogues.
Burrier, RE; Colwell, MR; Donley, ELR; Egnash, LA; Kirchner, FR; Palmer, JA; Smith, AM, 2017
)
0.46
" Of the reported serious adverse events (AEs), which included 11 deaths, none was attributable to study medication."( Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
Bukofzer, S; Clasen, K; Durkalski, V; Fontana, RJ; Ganger, D; Gottfried, M; Hameed, B; Hanje, AJ; Koch, D; Lee, WM; Little, L; Ravis, WR; Sherker, A; Stravitz, RT; Subramanian, RM, 2018
)
0.48
" The percentages of patients with any specific adverse event did not differ significantly between groups."( Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Bajaj, JS; Bhamidimarri, KR; Bukofzer, S; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Safadi, R; Thabut, D, 2021
)
0.62
" However, OP appears to be safe and should undergo further testing for treatment of hyperammonemia in hospitalized patients receiving treatment for the underlying precipitant of acute or overt HE."( Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Bajaj, JS; Bhamidimarri, KR; Bukofzer, S; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Safadi, R; Thabut, D, 2021
)
0.62
"Pentachlorophenol (PCP) is a ubiquitous environmental toxicant with various adverse effects."( Pentachlorophenol exposure induced neurotoxicity by disrupting citrulline metabolism in larvae and adult zebrafish.
Gu, Z; Li, L; Li, W; Pei, W; Qian, X; Wu, Q; Zhang, Y; Zhang, Z; Zhu, J, 2023
)
0.91

Pharmacokinetics

A population pharmacokinetic model was developed based on plasma concentrations of L-ornithine, phenylacetic acid, and phenylacetylglutamine. Plasma ammonia level was the primary pharmacodynamic variable.

ExcerptReferenceRelevance
"We have determined the pharmacokinetic parameters for diffusion of alpha-[5-14C]-difluoromethylornithine (DFMO) from blood to brain, blood to cerebrospinal fluid (CSF), 9L rat brain tumor to adjacent brain, and blood to the subcutaneously-implanted 9L tumor in rats, and within the CSF of beagle dogs."( Brain, CSF, and tumor pharmacokinetics of alpha-difluoromethylornithine in rats and dogs.
Byrd, DJ; Csejtey, J; Levin, VA, 1983
)
0.27
" DFMO levels were measured using an ion exchange chromatographic assay and pharmacokinetic studies were performed in patients treated at each dose level."( Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
Abeloff, MD; Baylin, SB; Blanc, O; Griffin, CA; Hermann, J; Luk, GD; Sjoerdsma, A; Slavik, M, 1984
)
0.27
" Finally, data from various pharmacokinetic studies together with basic physiology and biochemistry indicate that ARG is a net urea producer and ORN has a nitrogen-sparing effect, whereas CIT is neutral."( Pharmacokinetics of arginine and related amino acids.
Cynober, L, 2007
)
0.34
" However, its pharmacokinetic characteristics and tolerance to loading have not been studied to date."( Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study.
Bénazeth, S; Cynober, L; Darquy, S; Moinard, C; Neveux, N; Nicolis, I, 2008
)
0.35
" The objective of the present population pharmacokinetic modeling and simulation was to evaluate dose selection for target patient populations with a low body weight, ethnicity, and hepatic impairment in a global clinical study."( Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid.
Vilchez, RA; Wang, X, 2022
)
0.72
"A population pharmacokinetic model was developed based on plasma concentrations of L-ornithine, phenylacetic acid, and phenylacetylglutamine data from four clinical trials in healthy subjects and patients with stable cirrhosis or hospitalized adult patients with liver cirrhosis and hepatic encephalopathy."( Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid.
Vilchez, RA; Wang, X, 2022
)
0.72
" Plasma levels of ornithine and phenylacetic acid (PAA) and plasma/urinary levels of phenylacetylglutamine (PAGN) (primary metabolite of PAA) were regularly assessed; plasma ammonia level was the primary pharmacodynamic variable."( Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
Bajaj, JS; Bukofzer, S; Devarakonda, KR; Jamil, K; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Ram Bhamidimarri, K; Safadi, R; Thabut, D; Wang, L, 2022
)
0.72

Compound-Compound Interactions

alpha-difluoromethylornithine (DFMO) was administered in combination with human leukocyte interferon to human lymphoblastoid (Daudi) cells in culture. Two of the four cell lines display relative resistance.

ExcerptReferenceRelevance
" When doxorubicin hydrochloride (Adriamycin) was combined with DFMO, synergistic effects were noted at both DFMO concentrations."( Effect of alpha-difluoromethylornithine alone and in combination with doxorubicin hydrochloride, cis-diamminedichloroplatinum (II), and vinblastine sulfate on the growth of P3J cells in vitro.
Allen, ED; Natale, RB, 1986
)
0.27
"alpha-Difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, was administered in combination with human leukocyte interferon to human lymphoblastoid (Daudi) cells in culture."( Synergistic antiproliferative activity of leukocyte interferon in combination with alpha-difluoromethylornithine against human cells in culture.
Gutterman, JU; Rosenblum, MG, 1984
)
0.27
" On the basis of these prior findings, we investigated the effects of alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, alone and in combination with cis-diamminedichloroplatinum(II) (cisplatin), to which two of the four cell lines display relative resistance."( Inhibition of growth of human or hamster pancreatic cancer cell lines by alpha-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum(II).
Black, O; Chang, BK; Gutman, R, 1984
)
0.27
"The effects of alpha-difluoromethylornithine (DFMO; RMI 71782) in combination with vindesine or Adriamycin were investigated in three different animal tumor models."( Effects of alpha-difluoromethylornithine alone and combined with adriamycin or vindesine on L1210 leukemia in mice, EMT6 solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats.
Bartholeyns, J; Koch-Weser, J, 1981
)
0.26
"9% of the mean value in controls) in combination with an intermediate activity of L-ornithine: 2-oxoglutarate aminotransferase (40% of the mean value in controls)."( A lethal neonatal variant of carbamoyl-phosphate synthetase deficiency in combination with an intermediate activity of L-ornithine: 2-oxoglutarate amino-transferase.
Beemer, FA; Desplanque, J; Gerards, LJ; van der Heiden, C; van Dijk, HA, 1983
)
0.27
"Effects of polyamine (PA) synthesis inhibitors--alpha-difluoromethylornithinchloride (DFMO) and alpha-methylornithinchloride (MO)--separately or in combination with the epidermal growth factor (EGF)--on lysosome-phagosome fusion (P-LF) and F-actin content in murine peritoneal macrophages were studied using fluorescent dye Acridine orange for lysosome labelling, FITC-phalloidin for F-actin, and yeast cells as a target."( [Effect of polyamine synthesis inhibitors separately and in combination with epidermal growth factor on fusion of lysosomes with phagosomes and F-actin level in mouse peritoneal macrophages].
Beliaeva, TN; Bulychev, AG; Leont'eva, EA; Mozhenok, TP, 2000
)
0.31
" In this open-label, single-arm acute trial, seventeen healthy male volunteers were administered with a naturally occurring product of known terpenes-namely mastiha-after overnight fasting."( Modulation of Free Amino Acid Profile in Healthy Humans Administered with Mastiha Terpenes. An Open-Label Trial.
Amerikanou, C; Kaliora, AC; Kalogeropoulos, N; Papada, E; Smyrnioudis, I; Torović, L, 2018
)
0.48

Bioavailability

Global arginine bioavailability (GABR) was calculated by arginin divided by the sum of ornithine plus citrulline. The method was successfully applied to the quantitative determination of L-ornithine-L-aspartate in human plasma and could be useful for clinical and bioavailability investigations.

ExcerptReferenceRelevance
" Bioavailability of the 10 mg/kg dose was estimated as 58% from the urinary recoveries and as 54% from the areas under the plasma concentration curves (AUC 0 leads to infinity)."( Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase.
Alken, RG; Grove, J; Haegele, KD; Koch-Weser, J; Schechter, PJ, 1981
)
0.26
" A "priming" with difluoromethyl ornithine may therefore offer a means to enhance the epidermal accumulation of otherwise poorly absorbed methylglyoxal bis(guanylhydrazone)."( Effect of epidermal polyamine depletion on the accumulation of methylglyoxal bis(guanylhydrazone) in mouse skin.
Jänne, J; Käpyaho, K; Linnamaa, K, 1982
)
0.26
"Although reduced endothelial nitric oxide (NO) bioavailability has been demonstrated in arteriosclerotic vascular disease, the integrity of this system in sickle cell disease remains uncertain."( Divergent nitric oxide bioavailability in men and women with sickle cell disease.
Cannon, RO; Coles, WA; Csako, G; Gladwin, MT; Ognibene, FP; Panza, JA; Reiter, CD; Schechter, AN; Schenke, WH; Waclawiw, MA, 2003
)
0.32
"NO bioavailability and NO responsiveness are greater in women than in men with sickle cell disease and determines adhesion molecule expression."( Divergent nitric oxide bioavailability in men and women with sickle cell disease.
Cannon, RO; Coles, WA; Csako, G; Gladwin, MT; Ognibene, FP; Panza, JA; Reiter, CD; Schechter, AN; Schenke, WH; Waclawiw, MA, 2003
)
0.32
"Acute respiratory distress syndrome (ARDS) is associated with increased superoxide (O(2)(*-)) formation in the pulmonary vasculature and negation of the bioavailability of nitric oxide (NO)."( Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells.
Angelini, GD; Jeremy, JY; Muzaffar, S; Shukla, N; Srivastava, A, 2005
)
0.33
"Sickle cell disease is characterized by a state of nitric oxide resistance and limited bioavailability of l-arginine, the substrate for nitric oxide synthesis."( Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.
Blackwelder, WC; Gladwin, MT; Hazen, SL; Kato, GJ; Morris, CR; Morris, SM; Poljakovic, M; Sachdev, V; Vichinsky, EP; Wang, X, 2005
)
0.33
"These data support a novel mechanism of disease in which hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide."( Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.
Blackwelder, WC; Gladwin, MT; Hazen, SL; Kato, GJ; Morris, CR; Morris, SM; Poljakovic, M; Sachdev, V; Vichinsky, EP; Wang, X, 2005
)
0.33
" The method was successfully applied to the quantitative determination of L-ornithine-L-aspartate in human plasma and could be useful for clinical and bioavailability investigations."( Validated method for L-ornithine-L-aspartate analysis in human plasma by capillary electrophoresis.
Bieniecki, M; Kowalski, P; Lamparczyk, H; Oledzka, I, 2006
)
0.33
" Therapies that maximize arginine and nitric oxide bioavailability may benefit patients with thalassemia."( Hemolysis-associated pulmonary hypertension in thalassemia.
Kato, GJ; Kuypers, FA; Larkin, S; Lavrisha, L; Morris, CR; Singer, T; Vichinsky, EP, 2005
)
0.33
" This study provides the first evidence that increased denitrosylation leads to increased bioavailability of NO, independent of NOS activity, to promote sustained angiogenesis."( The release of nitric oxide from S-nitrosothiols promotes angiogenesis.
Ahmad, S; Ahmed, A; Ahmed, S; Al-Ani, B; Cudmore, M; Fujisawa, T; Hewett, PW, 2006
)
0.33
" Based on published data for the maximum observed plasma concentrations (Cmax) after administration of doses in the range 5 to 10 g, CIT appeared to present relatively better absorption and systemic bioavailability than ARG and ORN."( Pharmacokinetics of arginine and related amino acids.
Cynober, L, 2007
)
0.34
" Providing additional PRO in the diet to enhance PRO bioavailability for collagen biosynthesis does not result in increased collagen accumulation."( Proline precursors to sustain Mammalian collagen synthesis.
Barbul, A, 2008
)
0.35
" In conclusion, while NO bioavailability in mTALs is reduced during diabetes, free radical scavenging with tempol unmasks increased NO production that involves PP2B-dependent activation of NOS1 and NOS2."( PP2B-dependent NO production in the medullary thick ascending limb during diabetes.
Carmines, PK; Foster, JM; Pollock, JS, 2009
)
0.35
" We examined the relationship of global arginine bioavailability ratio (GABR) (defined as arginine/[ornithine + citrulline]) versus arginine and its catabolic metabolites to prevalence of significantly obstructive coronary artery disease (CAD) and incidence of major adverse cardiovascular events (MACE) (death, myocardial infarction, stroke) over a 3-year follow-up in 1,010 subjects undergoing elective cardiac catheterization."( Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk.
Brennan, DM; Cho, L; Hazen, SL; Tang, WH; Wang, Z, 2009
)
0.35
" Whereas previous studies have focused primarily on effects of high cholesterol diets on arginase expression and arginine metabolism in specific blood vessels, there is no information regarding the impact of lipid diets on arginase activity or arginine bioavailability at a systemic level."( Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets.
Chapman, R; Erdely, A; Hulderman, T; Kashon, M; Kepka-Lenhart, D; Morris, SM; Salmen-Muniz, R; Simeonova, PP, 2010
)
0.36
" NO bioavailability is linked to arginine, its metabolic products ornithine and citrulline, and methylarginines."( Quantification of arginine and its metabolites in human erythrocytes using liquid chromatography-tandem mass spectrometry.
Cavalca, V; Squellerio, I; Tremoli, E, 2011
)
0.37
" The bioavailability of NO plays a pivotal role in endothelial function and consequently in cardiovascular disease."( Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography.
Boehm, BO; Grammer, TB; März, W; Meinitzer, A; Pilz, S; Sourij, H; Winkelmann, BR, 2011
)
0.37
" Global arginine bioavailability (GABR) was calculated by arginine divided by the sum of ornithine plus citrulline."( Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography.
Boehm, BO; Grammer, TB; März, W; Meinitzer, A; Pilz, S; Sourij, H; Winkelmann, BR, 2011
)
0.37
" Further studies are warranted to elucidate the pathobiology and clinical relevance of the arginine bioavailability ratios in cardio-metabolic diseases."( Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography.
Boehm, BO; Grammer, TB; März, W; Meinitzer, A; Pilz, S; Sourij, H; Winkelmann, BR, 2011
)
0.37
"The hemolytic products cell-free oxyhemoglobin (FHb) and arginase-1 reduce nitric oxide (NO) bioavailability by scavenging NO and by degrading the NO precursor arginine to ornithine, respectively."( Hemolysis compromises nitric oxide-dependent vasodilatory responses in patients undergoing major cardiovascular surgery.
Bekers, O; Buurman, WA; Hanssen, SJ; Houben, AJ; Jacobs, MJ; Snoeijs, MG; van de Poll, MC; Windsant, IC, 2012
)
0.38
"Endothelial dysfunction is defined by reduced bioavailability of nitric oxide and has been shown to be associated with cardiovascular risk."( Multifactorial risk factor intervention in patients with Type 2 diabetes improves arginine bioavailability ratios.
Eder, M; Meinitzer, A; Pieber, TR; Sourij, H; Tripolt, NJ; Wascher, TC, 2012
)
0.38
" At baseline and 3 months, arginine, ornithine and citrulline were chromatographically determined after pre-column-derivatization followed by fluorescent detection, and arginine bioavailability ratios were calculated."( Multifactorial risk factor intervention in patients with Type 2 diabetes improves arginine bioavailability ratios.
Eder, M; Meinitzer, A; Pieber, TR; Sourij, H; Tripolt, NJ; Wascher, TC, 2012
)
0.38
"Intensified risk factor management significantly improved the global arginine bioavailability ratio (0."( Multifactorial risk factor intervention in patients with Type 2 diabetes improves arginine bioavailability ratios.
Eder, M; Meinitzer, A; Pieber, TR; Sourij, H; Tripolt, NJ; Wascher, TC, 2012
)
0.38
"In patients with Type 2 diabetes, intensified risk factor management improves arginine bioavailability ratios."( Multifactorial risk factor intervention in patients with Type 2 diabetes improves arginine bioavailability ratios.
Eder, M; Meinitzer, A; Pieber, TR; Sourij, H; Tripolt, NJ; Wascher, TC, 2012
)
0.38
"Up-regulation of arginase contributes to airways hyperresponsiveness (AHR) in asthma by reducing L-arginine bioavailability for the nitric oxide (NO) synthase isozymes."( Increased ornithine-derived polyamines cause airway hyperresponsiveness in a mouse model of asthma.
Gauvreau, GM; Grasemann, H; Inman, MD; Khanna, N; North, ML; Scott, JA, 2013
)
0.39
" Plasma amino acid profiling of two high fat (HF) feeding trials revealed that citrulline and ornithine concentrations are elevated in obese mice, while systemic arginine bioavailability (ratio of plasma arginine to ornithine + citrulline) is reduced."( Increased plasma citrulline in mice marks diet-induced obesity and may predict the development of the metabolic syndrome.
Boekschoten, MV; Dahlhoff, C; Daniel, H; de Wit, N; Eidens, MK; Giesbertz, P; Müller, M; Rubio-Aliaga, I; Sailer, M, 2013
)
0.39
" As a consequence, Indian women had lower arginine bioavailability (μmol · kg FFM⁻¹ · h⁻¹) in the fasting state (42."( Indian women of childbearing age do not metabolically conserve arginine as do American and Jamaican women.
Badaloo, A; Baker, TM; Bohren, KM; Dwarkanath, P; Hsu, JW; Jahoor, F; Kao, CC; Karnes, JM; Kurpad, AV; Thame, MM, 2015
)
0.42
" We demonstrate that 1) plasma indexes of L-arginine bioavailability and impairment of nitric oxide synthase function correlate with airway responsiveness to methacholine; 2) plasma levels of L-ornithine predict in vivo pulmonary arginase activity and airway function; and 3) acute arginase inhibition reduces in vivo pulmonary arginase activity to control levels and normalizes plasma L-ornithine, but not L-arginine, bioavailability in this model."( Plasma arginine metabolites reflect airway dysfunction in a murine model of allergic airway inflammation.
Grasemann, H; Huang, H; North, ML; Pencharz, P; Rafii, M; Scott, JA, 2015
)
0.42
"Compared with controls, fructose led to NAFLD with significantly higher visceral fat mass (128%), lower lean body mass (-7%), insulin resistance (135%), increased plasma triglycerides (TGs; 67%), and altered plasma amino acid concentrations with decreased Arg bioavailability (-27%)."( Citrulline and Nonessential Amino Acids Prevent Fructose-Induced Nonalcoholic Fatty Liver Disease in Rats.
Bergheim, I; Beutheu, S; De Bandt, JP; Jegatheesan, P; Nubret, E; Sarfati, G; Ventura, G, 2015
)
0.42
" The recently introduced "global arginine bioavailability ratio" (GABR; ratio of arginine to [ornithine+citrulline]) has been proposed as a reliable approximation of NO synthetic capacity in vivo."( Global arginine bioavailability, a marker of nitric oxide synthetic capacity, is decreased in PTSD and correlated with symptom severity and markers of inflammation.
Abu-Amara, D; Bersani, FS; Bierer, LM; Coy, M; Epel, ES; Flory, J; Lindqvist, D; Makotine, I; Marmar, C; Mellon, SH; Reus, VI; Wolkowitz, OM; Yehuda, R, 2016
)
0.43
"Elevation of arginase activity has been linked to vascular dysfunction in diabetes and hypertension by a mechanism involving decreased nitric oxide (NO) bioavailability due to L-arginine depletion."( Obesity-induced vascular dysfunction and arterial stiffening requires endothelial cell arginase 1.
Atawia, RT; Bagi, Z; Bhatta, A; Caldwell, RB; Caldwell, RW; Chen, J; Fouda, AY; Lucas, R; Toque, HA; Xu, Z; Yao, L, 2017
)
0.46
", the global arginine bioavailability ratio (GABR) and related serum amino acids, between MDD patients and non-depressed controls, and between remitted and non-remitted MDD patients."( Global arginine bioavailability ratio is decreased in patients with major depressive disorder.
Ali-Sisto, T; Honkalampi, K; Koivumaa-Honkanen, H; Lehto, SM; Mäntyselkä, P; Nandania, J; Ruusunen, A; Tolmunen, T; Valkonen-Korhonen, M; Velagapudi, V; Viinamäki, H, 2018
)
0.48
"Arginine bioavailability may be decreased in MDD."( Global arginine bioavailability ratio is decreased in patients with major depressive disorder.
Ali-Sisto, T; Honkalampi, K; Koivumaa-Honkanen, H; Lehto, SM; Mäntyselkä, P; Nandania, J; Ruusunen, A; Tolmunen, T; Valkonen-Korhonen, M; Velagapudi, V; Viinamäki, H, 2018
)
0.48
" The secondary objective was to investigate the effect of linagliptin treatment on arginine bioavailability ratios [Global arginine bioavailability ratio (GABR) and arginine to ornithine ratio (AOR)]."( Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
Aberer, F; Aziz, F; Brachtl, G; Brodmann, M; Dimsity, G; Hafner, F; Hödl, R; Meinitzer, A; Riedl, R; Sourij, H; Stojakovic, T; Strunk, D; Tripolt, NJ; Url, J, 2018
)
0.48
" No significant improvements were seen in the arginine bioavailability ratios (GABR; p = 0."( Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
Aberer, F; Aziz, F; Brachtl, G; Brodmann, M; Dimsity, G; Hafner, F; Hödl, R; Meinitzer, A; Riedl, R; Sourij, H; Stojakovic, T; Strunk, D; Tripolt, NJ; Url, J, 2018
)
0.48
"Linagliptin treatment in subjects with CAD and early T2DM did not improve endothelial function or the arginine bioavailability ratios."( Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
Aberer, F; Aziz, F; Brachtl, G; Brodmann, M; Dimsity, G; Hafner, F; Hödl, R; Meinitzer, A; Riedl, R; Sourij, H; Stojakovic, T; Strunk, D; Tripolt, NJ; Url, J, 2018
)
0.48
" We conclude that arginine bioavailability is important in T2D pathophysiology."( Changes in arginine are inversely associated with type 2 diabetes: A case-cohort study in the PREDIMED trial.
Arós, F; Bullo, M; Clish, C; Cofán, M; Corella, D; Dennis, C; Estruch, R; Fitó, M; Guasch-Ferré, M; Gutiérrez-Bedmar, M; Hu, FB; Lapetra, J; Liang, L; Martínez-González, MA; Papandreou, C; Razquin, C; Romaguera, D; Ros, E; Ruiz-Canela, M; Salas-Salvadó, J; Serra-Majem, L; Sorlí, JV; Toledo, E; Wang, DD; Yu, E, 2019
)
0.51
" One of the biggest problems of these compounds, however, is their very short bioavailability due to instant metabolism and rapid excretion."( Poly(ornithine)-based self-assembling drug for recovery of hyperammonemia and damage in acute liver injury.
Ibayashi, Y; Lee, Y; Nagasaki, Y; Ngo, DN; Nishikawa, Y; Vong, LB, 2019
)
0.51
" Lung and liver tissues from EC Arg1 KO mice showed respectively increase or decrease in nitrosyl-heme species, indicating that the lack of endothelial Arg1 affects NO bioavailability in these organs."( Downregulation of eNOS and preserved endothelial function in endothelial-specific arginase 1-deficient mice.
Carlström, M; Cortese-Krott, MM; Grandoch, M; Guimaraes Braga, DD; Heuser, SK; Kelm, M; Leo, F; Li, J; LoBue, A; Lundberg, JO; Montero, L; Olsson, A; Pernow, J; Schmitt, JP; Schmitz, OJ; Schneckmann, R; Srivrastava, T; Suvorava, T; Weitzberg, E; Zhuge, Z, 2022
)
0.72
"The long-term prognostic value of the bioavailability of L-arginine, an important source of nitric oxide for the maintenance of vascular endothelial function, has not been investigated fully."( A Low Arginine/Ornithine Ratio is Associated with Long-Term Cardiovascular Mortality.
Adachi, T; Hitomi, Y; Ido, Y; Ikegami, Y; Ishinoda, Y; Iwashita, M; Kagami, K; Kawai, A; Masaki, N; Miyazaki, K; Nagatomo, Y; Namba, T; Takase, B; Taruoka, A; Toya, T; Yasuda, R; Yumita, Y, 2023
)
0.91
" l-arginine-derived markers of nitric oxide (NO) bioavailability (i."( Effects of l-Arginine Plus Vitamin C Supplementation on l-Arginine Metabolism in Adults with Long COVID: Secondary Analysis of a Randomized Clinical Trial.
Calvani, R; Ciciarello, F; Coelho-Júnior, HJ; Di Mario, C; Galluzzo, V; Gervasoni, J; Gremese, E; Landi, F; Lomuscio, S; Marini, F; Marzetti, E; Paglionico, AM; Picca, A; Santucci, L; Tolusso, B; Tosato, M; Urbani, A, 2023
)
0.91

Dosage Studied

The optimal dosage of ornithine alpha-ketoglutarate (OKG) for repleting tissue glutamine (Gln) concentrations and maintaining N homeostasis after injury is unknown. After oral dosing of 110 mg/kg arginine, Ornithine plasma concentrations rose from 54 to 148 micromol/l after 2h.

ExcerptRelevanceReference
" The effects on the amino acids are not due to a change in the food intake caused by dosing with arsenate."( The effects of sodium arsenate on the free amino acid levels in erythrocytes and plasma in rats.
Kilroe-Smith, TA; McLoughlin, JL, 1979
)
0.26
" Dose-response curver were different for L(+) and D(+)arginine, and the suppressor effect of glucose on the response to L(+) arginine was not detected in the presence of D(+) arginine or homoarginine."( Glucagon secretion induced by natural and artificial amino acids in the perfused rat pancreas.
Assan, R; Attali, JR; Ballerio, G; Boillot, J; Girard, JR, 1977
)
0.26
"01) at T = 45 and 90 min for all three dosage levels."( Ornithine supplementation and insulin release in bodybuilders.
Bucci, LR; Hickson, JF; Pivarnik, JM; Wolinsky, I, 1992
)
0.28
" We could not demonstrate a gene dosage effect in oxidation values."( Comparison of ornithine metabolism in hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome, lysinuric protein intolerance and gyrate atrophy fibroblasts.
Botschner, J; Scriver, CR; Simell, O; Smith, DW, 1989
)
0.28
" Maternal weight gain was significantly reduced in a dose-response manner, but litter size and pup weight on postnatal day (PND) 1 were unaffected."( Effect of prenatal imipramine exposure on development of the postnatal rat heart and brain.
Delongchamp, RR; Harmon, JR; Kimmel, GL; Webb, PJ, 1986
)
0.27
" The overproduction of ornithine decarboxylase by the tumor cells grown under the pressure of difluoromethylornithine was at least partly attributable to a 10 to 20-fold increase in the total gene dosage of ornithine decarboxylase involving an amplification of several genes of the gene family."( Difluoromethylornithine-induced amplification of ornithine decarboxylase genes in Ehrlich ascites carcinoma cells.
Alhonen-Hongisto, L; Jänne, J; Jänne, OA; Kallio, A; Kontula, KK; Seppänen, P; Sinervirta, R, 1985
)
0.27
" Median effect analysis of the DFMO + IFN inhibition of C8161 cells demonstrated that the 2 agents interacted synergistically over the entire dose-response curve."( Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid.
Bregman, MD; Meyskens, FL, 1986
)
0.27
" Plating efficiency assays were used to generate ADR dose-response survival curves for DFMO-treated and control cultures."( Reduced cytocidal efficacy for adriamycin in cultured human carcinoma cells depleted of polyamines by difluoromethylornithine treatment.
Block, AL; Komar, KA; Naujokas, MF; Seidenfeld, J, 1986
)
0.27
" Plating efficiency assays were used to generate BCNU dose-response survival curves for DFMO-treated and control cells."( Chemosensitization of cultured human carcinoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by difluoromethylornithine-induced polyamine depletion.
Komar, KA; Seidenfeld, J, 1985
)
0.27
" A dose-response curve was developed for each interferon in which the maximum dose applied gave at least 30% growth inhibition of control values after 96-128 h of continuous exposure."( The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human cell lines.
Harvey, HA; Leitzel, KE; Lipton, A; Pegg, AE; Wolf, LM, 1985
)
0.27
" One group, termed stuporous (AS), received only enough ammonium acetate to interfere with grooming and exploratory activity; this dosage was insufficient to completely block the righting response, which was absent in the AC group."( Disruption of the blood-brain barrier in hyperammonemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine.
Chandler, MD; McCandless, DW; Sears, ES, 1985
)
0.27
" In addition, a simplified, once daily dosage of DFMO appears adequate."( Inhibition of ornithine decarboxylase activity by small doses of alpha-difluoromethylornithine.
Loprinzi, CL; Verma, AK, 1985
)
0.27
" Vomiting, necessitating dosage reduction, was a significant problem at the highest dose administered."( Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor.
Estey, E; Freireich, EJ; Keating, MJ; Maddox, AM; McCredie, KE, 1985
)
0.27
"" The precision of the method derives from a direct comparison between the cumulative dose-response curve of an agonist of unknown potency acting on one hemibladder and that of a reference compound acting on the contralateral hemibladder."( A sensitive hydroosmotic toad bladder assay. Affinity and intrinsic activity of neurohypophyseal peptides.
Eggena, P; Schwartz, IL; Walter, R, 1968
)
0.25
" Dose-response studies with MGBG (0 to 30 microM for 40 to 48 hr) revealed that, of the parameters related to polyamine metabolism (i."( Biochemical and ultrastructural characterization of human cell variants resistant to the antiproliferative effects of methylglyoxal bis(guanylhydrazone).
Kramer, DL; Porter, CW; Wiseman, A; Zychlinski, L, 1983
)
0.27
" As a result of treatment with the highest intravenous dosage (1000 mg/kg/day), villous atrophy of the mucosa was observed by light and scanning electron microscopy in the canine small intestine."( Intestinal changes caused by DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.
Diekema, KA; Gibson, JP; Loudy, DE; McCann, PP; Sprinkle, DJ; Yarrington, JT, 1983
)
0.27
" Treatment is applied at a dosage of 25 g per day with intravenous nutrition and/or oral feeding (150 Kcal/g of excreted nitrogen)."( [Effects of ornithine alpha-ketoglutarate on the nutritional state of intensive-care patients].
Crignon, JJ; Delbar, M; Demarcq, JM; Trochu, G, 1984
)
0.27
" Toxic symptoms occurred in all seven patients when AOAA dosage was increased beyond 2 mg per kilogram per day, and included drowsiness, ataxia, seizures, and psychotic behavior."( Failure of aminooxyacetic acid therapy in Huntington disease.
Allan, BM; Baird, PA; Hansen, S; MacLeod, PM; Perry, TL; Wright, JM, 1980
)
0.26
" Dosage of CSF polyamines was proved to be useful in monitoring patients with medulloblastomas and others malignancies with meningeal involvement."( Polyamines: current review and their perspectives in neurosurgery.
Occhiogrosso, M; Pierangeli, E; Vailati, G,
)
0.13
" Both marked antitumor effects and side effects were observed in mice treated at the dosage of DFMO 500 mg/kg/day and/or MGBG 50 mg/kg/day and/or MGBG 30 mg/kg/day brought about significant antitumor effects as well as less side effects."( [Antitumor effects of polyamine synthesis inhibitors based on major premise of treatment for human malignant tumor].
Fujimoto, S; Hirose, S; Igarashi, K; Okui, K; Shrestha, RD; Terao, K, 1982
)
0.26
" Diluted plasma from normal and acromegalic dogs resulted in a dose-response curve parallel to the standard curve."( Radioimmunoassay of canine growth hormone.
Eigenmann, JE; Eigenmann, RY, 1981
)
0.26
" Additionally, one of our patients responded to high dosage vitamin B6 with a 27% reduction in plasma ornithine."( Clinical and biochemical heterogeneity in gyrate atrophy.
Bron, AJ; Kaiser-Kupfer, MI; Valle, D, 1980
)
0.26
" It is, however, obvious that both in rats and mice the severity of symptoms depends not only on dose and dosing schedule of TAA, but also on strain and body weight (age)."( Effects of inhibition of ornithine aminotransferase on thioacetamide-induced hepatogenic encephalopathy.
Grauffel, C; Knödgen, B; Sarhan, S; Seiler, N, 1993
)
0.29
" Vasodilator responses to saline and each amino acid were compared as the area under dose-response curves with single-factor analysis of variance (ANOVA)."( Arginine, lysine and ornithine as vasodilators in the forearm of man.
Barr, CS; Rhodes, P; Struthers, AD, 1996
)
0.29
"Groups of pigmented rabbits, six in each group, were dosed during 10 weeks with one of the substances under investigation, and one untreated group was the control."( Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine.
Kobayashi, T; Olsen, EB; Ribel-Madsen, SM; Trier, K, 1999
)
0.3
" unstimulated conditions), the nitric oxide synthase (NOS) inhibitor L-NIO (L-N(5)-(1-iminoethyl) ornithine, 10(-5) and 10(-4) M), caused a marked vasoconstriction (20%), indicating a basal nitrergic vasodilator tone, while the dose-response curve of the NO donor SIN-1 (3-morpholinosydnonimine) showed a dose-dependent vasodilator effect."( Control of cardiovascular function in the icefish Chionodraco hamatus: involvement of serotonin and nitric oxide.
Acierno, R; Pellegrino, D; Tota, B, 2003
)
0.32
"The optimal dosage of ornithine alpha-ketoglutarate (OKG) for repleting tissue glutamine (Gln) concentrations and maintaining N homeostasis after injury is unknown."( Dose dependency of the effect of ornithine alpha-ketoglutarate on tissue glutamine concentrations and hypercatabolic response in endotoxaemic rats.
Coudray-Lucas, C; Cynober, L; Jardel, A; Pernet, P; Schneid, C, 2004
)
0.32
" Our work provides a revised genetic map of IP metabolism in yeast and evidence for dosage compensation between IPs and PP-IPs downstream of I(1,4,5)P3 in the regulation of nucleocytoplasmic processes."( Molecular definition of a novel inositol polyphosphate metabolic pathway initiated by inositol 1,4,5-trisphosphate 3-kinase activity in Saccharomyces cerevisiae.
Bastidas, RJ; Seeds, AM; York, JD, 2005
)
0.33
" BetaA toxicity was measured in septal glia, via a dose-response experiment, by quantifying the effects of three different doses (0."( Beta-amyloid toxicity in embryonic rat astrocytes.
Assis-Nascimento, P; Jarvis, KM; Montague, JR; Mudd, LM, 2007
)
0.34
" After oral dosing of 110 mg/kg arginine, ornithine plasma concentrations rose from 54 to 148 micromol/l after 2h and were back to baseline after 24h."( Determination of ornithine in human plasma by hydrophilic interaction chromatography-tandem mass spectrometry.
Bode-Böger, SM; Martens-Lobenhoffer, J; Postel, S; Tröger, U, 2007
)
0.34
" We defined each agent's clinical potency index (CPI) as the AUC achieved with standard pediatric dosing regimens divided by the in vitro IC50."( Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias.
Adamson, PC; Norris, RE, 2010
)
0.36
" In addition, Orn/Trp induced a silencing effect at lower doses than STR-R8, as evidenced by dose-response data."( Ornithine and tryptophan analogs as efficient polycations for short interference RNA delivery to tumor cells.
Harashima, H; Hatakeyama, H; Sato, Y, 2010
)
0.36
" Ammonia levels could shown to be reduced for up to 24 h in animal models until 120 h in patients with repeated dosing of the drug."( Ornithine phenylacetate revisited.
Jalan, R; Jover-Cobos, M; Noiret, L; Sharifi, Y, 2013
)
0.39
" Further clinical evaluation is warranted to investigate whether a low dosage of these antifolates can elicit immunosuppressive effects equivalent to MTX, and whether they are superior to MTX in patients who fail to respond to MTX."( Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.
Assaraf, YG; Dijkmans, BA; Gerards, AH; Jansen, G; Lems, WF; Oerlemans, R; Scheper, RJ; van der Heijden, JW, 2014
)
0.4
"With a flat dosing algorithm, special consideration must be given to patients with a small body size (i."( Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid.
Vilchez, RA; Wang, X, 2022
)
0.72
" However, currently, there are no recommendations set by national health agencies for tolerable upper intake levels (UL) for amino acids because of a lack of well-conducted human dose-response trials."( Tolerable Upper Intake Level for Individual Amino Acids in Humans: A Narrative Review of Recent Clinical Studies.
Elango, R, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Product(s))

Product Categories

Product CategoryProducts
Active Lifestyle & Fitness2
Vitamins & Supplements1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Animal PAK - The Ultimate Training Pack -- 30 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Animal PAK - The Ultimate Training Pack -- 44 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Olympian Labs Sea Nourishment Cran-Raspberry -- 32 fl ozOlympian LabsVitamins & SupplementsLipase, citric acid, Alanine, Arginine, Vitamin C, Aspartic Acid, Barium, Beta Carotene, Bismuth, Boron, Bromine, Cadmium, Cellulase, Cesium, Chloride, Chromium, citric acid, Citrulline, Cobalt, Cysteine, Cystine, Vitamin E, fructose, Germanium, Vitamin E, Glutamine, Glycine, Gold, Histidine, Hydrogen, Indium, Iodine, Iridium, Lanthanum, Lithium, Manganese, Molybdenum, Vitamin B, Nickel, Niobium, Ornithine, Osmium, Palladium, Phosphorus, Platinum, Proline, Rhodium, Rubidium, Selenium, Serine, Silver, Strontium, Sulfur, Taurine, Tellurium, Thallium, Tin, Titanium, Tungsten, CoQ7, CoQ8, CoQ9, Uranium, Vanadium2024-11-29 10:47:42

Roles (3)

RoleDescription
hepatoprotective agentAny compound that is able to prevent damage to the liver.
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
ornithineAn alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (48)

PathwayProteinsCompounds
Amino acid synthesis and interconversion (transamination)2343
Urea Cycle1325
Arginine and Proline Metabolism2047
Spermidine and Spermine Biosynthesis614
Prolidase Deficiency (PD)2047
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)2047
Hyperprolinemia Type II2047
Hyperprolinemia Type I2047
Prolinemia Type II2047
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)2047
Ornithine Aminotransferase Deficiency (OAT Deficiency)2047
Argininemia1325
Argininosuccinic Aciduria1325
Citrullinemia Type I1325
Ornithine Transcarbamylase Deficiency (OTC Deficiency)1325
Carbamoyl Phosphate Synthetase Deficiency1325
Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency2047
Hyperornithinemia with Gyrate Atrophy (HOGA)2047
Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]2047
L-Arginine:Glycine Amidinotransferase Deficiency2047
Arginine Metabolism2848
Ornithine Metabolism1631
Arginine and Proline metabolism ( Arginine and Proline metabolism )4255
2-Oxo acid + L-Ornithine = L-Amino acid + L-Glutamate 5-semialdehyde ( Arginine and Proline metabolism )14
L-Arginine + Glycine = L-Ornithine + Guanidino-acetic acid ( Glycine and Serine metabolism )14
Glycine and Serine metabolism ( Glycine and Serine metabolism )3649
22q11.2 copy number variation syndrome228
T cell modulation in pancreatic cancer459
Metabolic Epileptic Disorders2589
ornithine biosynthesis (arginine degradation)04
superpathway of arginine and ornithine degradation027
arginine degradation VII (arginase 3 pathway)06
arginine degradation I (arginase pathway)011
arginine degradation VII012
arginine biosynthesis I027
spermine biosynthesis II08
ornithine biosynthesis017
polyamine biosynthesis08
arginine degradation (arginase pathway)04
D-arginine and D-ornithine metabolism09
AtMetExpress overview0109
One-carbon donor022
Trans-sulfuration, one-carbon metabolism and related pathways053
Methionine de novo and salvage pathway148
Metabolism overview078
Biochemical pathways: part I0466
Amino acid metabolism094
Glucose homeostasis021

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ARGINASE 1Rattus norvegicus (Norway rat)Ki1,000.000010.0000505.00001,000.0000AID977610
Chain A, Arginase 1Rattus norvegicus (Norway rat)Ki1,000.000010.0000505.00001,000.0000AID977610
Chain A, ARGINASE 1Rattus norvegicus (Norway rat)Ki1,000.000010.0000505.00001,000.0000AID977610
Chain A, L-ARGININE\\:GLYCINE AMIDINOTRANSFERASEHomo sapiens (human)Ki253.0000253.0000253.0000253.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain E, LYSINE, ARGININE, ORNITHINE-BINDING PROTEINSalmonella enterica subsp. enterica serovar TyphimuriumKd0.03000.01400.18130.5000AID977611
Chain E, LYSINE, ARGININE, ORNITHINE-BINDING PROTEINSalmonella enterica subsp. enterica serovar TyphimuriumKd0.03000.01400.18130.5000AID977611
Chain E, LYSINE, ARGININE, ORNITHINE-BINDING PROTEINSalmonella enterica subsp. enterica serovar TyphimuriumKd0.03000.01400.18130.5000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID233320Bitter threshold value; NB denotes 'Not bitter'1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID1132043Binding affinity to pyridoxal-phosphate1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Analogues of ornithine as inhibitors of ornithine decarboxylase. New deductions concerning the topography of the enzyme's active site.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001Biochemistry, Mar-06, Volume: 40, Issue:9
Mechanistic and metabolic inferences from the binding of substrate analogues and products to arginase.
AID1811Experimentally measured binding affinity data derived from PDB2001Biochemistry, Mar-06, Volume: 40, Issue:9
Mechanistic and metabolic inferences from the binding of substrate analogues and products to arginase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1997The EMBO journal, Jun-16, Volume: 16, Issue:12
Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis.
AID1811Experimentally measured binding affinity data derived from PDB1997The EMBO journal, Jun-16, Volume: 16, Issue:12
Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis.
AID1811Experimentally measured binding affinity data derived from PDB1994The Journal of biological chemistry, Oct-21, Volume: 269, Issue:42
Structural basis for multiple ligand specificity of the periplasmic lysine-, arginine-, ornithine-binding protein.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1994The Journal of biological chemistry, Oct-21, Volume: 269, Issue:42
Structural basis for multiple ligand specificity of the periplasmic lysine-, arginine-, ornithine-binding protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,998)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902863 (57.28)18.7374
1990's602 (12.04)18.2507
2000's640 (12.81)29.6817
2010's660 (13.21)24.3611
2020's233 (4.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials100 (1.93%)5.53%
Reviews188 (3.62%)6.00%
Case Studies198 (3.81%)4.05%
Observational6 (0.12%)0.25%
Other4,700 (90.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]